Major Depression Clinical Trials

Find Major Depression Clinical Trials Near You

A Double-Blind, Placebo-Controlled, Parallel Group, Efficacy and Safety Study of ACP-211 Monotherapy in Adults With Major Depressive Disorder and Inadequate Response to Antidepressant Treatment

Status: Recruiting
Location: See all (26) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY

The goal of this clinical trial is to learn if ACP-211 can help treat adults with major depressive disorder (MDD) who have not improved with antidepressant therapy (ADT), including those with treatment resistant depression (TRD). The main questions the study aims to answer are: * Does ACP-211 work better than a placebo (a look-alike capsule with no medicine) to reduce symptoms of depression? * What adverse events do participants have when taking ACP-211?

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 65
Healthy Volunteers: f
View:

• Adults ≥18 and ≤65 years of age

• Provides written informed consent

• Clinical diagnosis of MDD

• History of inadequate response to at least two antidepressants, with at least one inadequate response documented during the current episode

• Currently treated with an approved antidepressant at a stable dose prior to Screening

• MADRS total score ≥28, CGI-S score ≥4 , and QIDS-SR16 score ≥16 at Screening and Baseline

• Females of childbearing potential must have a negative pregnancy test and agree to use acceptable contraception; males must agree to use barrier protection and refrain from sperm donation

Locations
United States
Alabama
University of Alabama at Birmingham
ACTIVE_NOT_RECRUITING
Birmingham
California
Inland Psychiatric Medical Group
RECRUITING
Chino
Behavioral Research Specialists, LLC
RECRUITING
Glendale
Kadima Neuropsychiatry Institute
RECRUITING
La Jolla
PNS Clinical Research LLC dba ATP Clinical Research
RECRUITING
Orange
Colorado
Mountain View Clinical Research
RECRUITING
Denver
Florida
New Access Research and Medical Services, Inc.
RECRUITING
Fort Myers
The Medici Medical Research
RECRUITING
Hollywood
Sandhill Research, LLC/DBA Accel Research Sites
ACTIVE_NOT_RECRUITING
Largo
Clinical Neuroscience Solutions, Inc.
RECRUITING
Orlando
IPTB Clinical Research
RECRUITING
Tampa
Neuroscience Research Institute, Inc.
RECRUITING
West Palm Beach
Massachusetts
Adams Clinical, Inc.
RECRUITING
Watertown
Vitalix Clinical, Inc.
RECRUITING
Worcester
Missouri
St. Charles Psychiatric Associates, Inc. dba Midwest Research Group
RECRUITING
Saint Charles
Mississippi
Precise Research Centers
RECRUITING
Flowood
North Carolina
Magnolia Clinical Research, LLC
RECRUITING
Cary
Nebraska
Alivation Research, LLC
RECRUITING
Lincoln
New Jersey
CenExel Hassman Research Institute, LLC
ACTIVE_NOT_RECRUITING
Marlton
Nevada
Redbird Research LLC
RECRUITING
Las Vegas
New York
Integrative Clinical Trials LLC
RECRUITING
Brooklyn
Ohio
Neuro-Behavioral Clinical Research
RECRUITING
North Canton
Texas
Baylor College of Medicine
RECRUITING
Houston
Dynamed Clinical Research LP d/b/a DM Clinical Research
WITHDRAWN
Houston
Olympus Clinical Research, LLC
RECRUITING
Katy
Family Psychiatry of The Woodlands
RECRUITING
The Woodlands
Contact Information
Primary
Sandy Filosi
sfilosi@ACADIA-Pharm.com
+1(609) 250-6920
Backup
Lori Lykens
lori.lykens@acadia-pharm.com
+1(609) 250-6917
Time Frame
Start Date: 2025-11-14
Estimated Completion Date: 2027-09
Participants
Target number of participants: 153
Treatments
Experimental: ACP-211 600 mg
ACP-211 600 mg, administered orally twice weekly
Experimental: ACP-211 300 mg
ACP-211 300 mg, administered orally twice weekly
Placebo_comparator: Placebo
Matching placebo, administered orally twice weekly
Related Therapeutic Areas
Sponsors
Leads: ACADIA Pharmaceuticals Inc.

This content was sourced from clinicaltrials.gov